Design, scale, and release plasma-derived therapeutics with a Canadian partner who integrates manufacturing, QC, and regulatory pathways.
Flexible production suites licensed for commercial distribution in Canada, Europe, and key global markets.
Hybrid Cohn and chromatographic trains with redundant utilities and validated hold times.
Grade A/B isolators with bilingual labelling and country-specific packaging workflows.
Stage-gated methodology covering feasibility, engineering, validation, and commercial ramp.
In-house laboratories combine compendial testing with advanced characterisation to accelerate release.
| Test | Turnaround | Availability |
|---|---|---|
| Protein potency (SRID, nephelometry) | 48h | On-demand |
| Viral safety (PCR, NAT, adventitious agents) | 72h | Weekly campaigns |
| Impurity profiling (HPLC, mass spectrometry) | 96h | Project-based |
| Stability studies & trending | Protocol-driven | Annual plan |
Purpose-built packages align with your regulatory roadmap and commercial strategy.
Four-week sprint to assess plasma stream compatibility, yield, and purity targets.
Comprehensive support through validation, filing, and market entry.
Long-term alliances for capacity planning, ESG, and co-development.
Bilingual experts guide regulatory strategy, market access, and supply resilience.
Share your scope and our specialists will coordinate a bilingual discovery session within two business days.